Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that it had received notification from GlaxoSmithKline (LON:GSK) that Relenza sales were A$462 million and indicative royalties were A$32.3 million, for the three months ended 31 March 2009.

Indicative royalties for the nine months to 31 March 2009 total A$36.1 million.

Biota CEO Peter Cook attributed the performance to recent significant orders for pandemic stockpiling from the UK and Japanese Governments.

About Biota Holdings Limited

Contact

Investor / Analyst Enquiries
Biota Holdings Limited
Peter Cook
Tel: +61-3-9915-3720

Damian Lismore
Tel: +61-3-9915-3721


Link: Biota Holdings Limited (ASX:BTA) Announced Thier Relenza Royalty for March 2009 quarter At $32.3 Million


Related Companies

GlaxoSmithKline plc
      

Biota Holdings Limited
       


Biota Holdings Limited

iSOFT Group Limited (ASX:ISF) Appoints Dr. James Fox As Deputy Chairman

Australian Market Report of August 13: US Economy Stabilizing

iSOFT Group Limited (ASX:ISF) Appoints Dr. James Fox As Non-Executive Director

Biota Holdings Limited (ASX:BTA) Notes Important Initiatives By GSK to Respond to the New Influenza A (H1N1) Strain

Australian Market Report of March 30: A Slowdown after Weeks of Rallies


Read More

GlaxoSmithKline plc

Dart Energy Limited (ASX:DTE) Executive And Management Team In-Place To Deliver Growth

Asian Markets Overview of February 22

Biota Holdings Limited (ASX:BTA) Notes Important Initiatives By GSK to Respond to the New Influenza A (H1N1) Strain

Biota Holdings Limited (ASX:BTA) Revised Relenza Royalty For December 2008 Quarter

Biota Holdings Limited (ASX:BTA) GSK Imports Additional Relenza To Japan


Read More